This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Lia M Haynes: Innovator in RSV Immunization
Introduction
Lia M Haynes is a prominent inventor based in Lithonia, GA (US). She has made significant contributions to the field of immunology, particularly in the development of vaccines for respiratory syncytial virus (RSV). With a total of 2 patents, her work is crucial in the fight against RSV infections.
Latest Patents
Lia M Haynes' latest patents focus on anti-RSV immunogens and methods of immunization. These patents provide immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, as components of vaccines. The inventive compositions are designed to be both prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The immunogens include specific regions of the RSV G protein, particularly amino acid residues 164-176 of the RSV G A2 protein or analogs thereof. This innovative immunogen can be used alone or in combination with other polypeptides, such as the RSV G protein amino acid residues 155-206, or with other vaccines, including live RSV vaccines or inactivated RSV vaccines.
Career Highlights
Throughout her career, Lia M Haynes has worked with notable organizations, including the United States of America, as represented by the Secretary, Department of Health and Human Services, and the University of Georgia Research Foundation Inc. Her work has been instrumental in advancing the understanding and treatment of RSV.
Collaborations
Lia has collaborated with esteemed colleagues such as Ralph A Tripp and Larry J Anderson. These partnerships have further enhanced her research and contributions to the field.
Conclusion
Lia M Haynes is a dedicated inventor whose work in RSV immunization is paving the way for innovative treatments and vaccines. Her contributions are vital in addressing the challenges posed by RSV infections.